10x Genomics and Lausanne University Hospital Partner to Advance Cancer Diagnosis Research with Single-cell and Spatial Technologies

On 29 July 2026, 10x Genomics and Lausanne University Hospital collaborate to speed up research in single-cell and spatial biology. Their partnership aims to enhance precision cancer diagnostics, personalized medicine, biomarker discovery, clinical innovation, and the global advancement of data-driven oncology care.

10x Genomics partners with Lausanne University Hospital (CHUV) to improve cancer diagnostics through single-cell and spatial biology technologies, linking genomic research with clinical oncology to accelerate understanding of tumor biology and progress of personalized treatments.  Spatial biology maintains cell arrangement, revealing interactions prompting tumor growth and response. Single-cell analysis observes individual cells, identifying various populations and mutations.

The alliance highlights the emerging role of genomics and digital health, with large datasets supporting machine learning to discover hidden patterns. Combining 10x Genomics' platforms with CHUV's expertise targets to improve biomarker discovery, diagnosis, and therapy, enabling personalized treatments.  The rising focus on regulatory approval and ongoing validation of such collaboration accelerates medical advancements, patient stratification, and personalized oncology, setting progress toward data-driven cancer care.

Impact on the Biotechnology Industry

The global biotechnology market size is accounted at USD 1.77 trillion in 2025 and predicted to increase from USD 2.02 trillion in 2026 to approximately USD 6.34 trillion by 2035, representing a CAGR of 13.61% from 2026 to 2035.

According to Precedence Research, as hospitals explore cancer biology, demand for advanced genomic tools grows, allowing new diagnostics with cutting-edge instruments and biotechnology software. The corporation advances biotechnology in precision medicine and diagnostics by focusing on genomic sequencing, single-cell technologies, spatial biology, and lab automation infrastructure. These partnerships promote investment in translational research, connecting lab discoveries to spatial biology and precision diagnostics that have long-term clinical applications.

Biotechnology is moving from research to a vital healthcare innovator, leveraging genomics, AI, automation, and validation to enhance cancer diagnostics and personalized medicine. The expansion of biomarker-focused firms as cellular data enhances disease signatures, supporting early diagnosis, monitoring, and targeted therapies. Additionally, the collaboration integrates sequencing, AI, cloud analytics, and clinical decision-making to streamline workflows.

Impact on the Oncology Industry

The global oncology market size was calculated at USD 250.88 billion in 2025 and is predicted to increase from USD 279.73 billion in 2026 to approximately USD 732.45 billion by 2035, expanding at a CAGR of 11.31% from 2026 to 2035.

According to Precedence Research, clinicians can access detailed cellular and spatial data to improve disease classification and cancer therapy. Technologies such as single-cell and spatial biology enhance diagnostic accuracy by providing subtle molecular understandings. This partnership serves as a precision medicine standard in oncology, influencing healthcare providers and cancer care by tailoring treatments, improving diagnosis, and controlling costs.

Academic medical centers and cancer care hubs are to develop advanced diagnostics, labs, and research, expanding patient access to new treatments. Hospitals become innovation hubs that advance next-gen diagnostics and transform oncology. These partnerships promote investments in molecular and genomic sequencing, digital pathology, and multidisciplinary oncology, which are crucial to data-driven healthcare.

Impact on the Precision Medicine Industry

The global precision medicine market size is estimated at USD 119.03 billion in 2025 and is predicted to increase from USD 138.67 billion in 2026 to approximately USD 537.17 billion by 2035, expanding at a CAGR of 16.26% from 2026 to 2035.

According to Precedence Research, the need for accurate biomarkers enables patient selection, response prediction, and disease tracking, thereby accelerating biomarker discovery and patient stratification, especially in immuno-oncology. The healthcare industry benefits from advances in single-cell and spatial biology to improve drug discovery. Spatial biology offers visual insights into immune-tumor interactions for new treatments.  Understanding individual cell functions in tumor environments helps identify targeted therapies.

Firms may partner with biotech companies to develop companion diagnostics, aligning with the shift toward precision medicine. Improved diagnostics, lower costs by streamlining recruitment, boosting trial efficiency, and supporting regulatory approval. They also enable value-based healthcare by matching therapies to responsive patients. Overall, this collaboration reflects a move toward personalized treatments, combining genomics, biomarkers, AI, and targeted therapies for superior cancer care.

Expert Opinion

From the expert's perspective, the partnership between 10x Genomics and Lausanne University Hospital advances precision oncology by translating genomic innovations into practical diagnostic tools that enhance patient care. Widespread adoption depends on regulatory approval, physician training, reimbursement, and the suggestion of better outcomes. It combines single-cell analysis and spatial biology to deepen understanding of cancer and its interactions with the tumor microenvironment, supporting personalized treatments.

The partnership symbolizes a move toward personalized, data-driven cancer diagnostics that could accelerate global precision oncology, support targeted therapies, improve clinical decisions, and enhance patient survival and quality of life. This collaboration reflects a broader industry transition toward multidisciplinary targets across hospitals, biotechnology, and pharmaceuticals, with future cancer therapies relying on integrated solutions such as sequencing, AI, and digital pathology.